Cessation of Targeted Therapy After a Complete Response in BRAF-mutant Advanced Melanoma: A Case Series

British Journal of Cancer - United Kingdom
doi 10.1038/bjc.2016.321
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Comparative Efficacy of Combination Immunotherapy and Targeted Therapy in the Treatment of BRAF-mutant Advanced Melanoma: A Matching-Adjusted Indirect Comparison

Immunotherapy
OncologyAllergyImmunology
2019English

Ineffective Anti PD-1 Therapy After BRAF Inhibitor Failure in Advanced Melanoma

BMC Cancer
Cancer ResearchOncologyGenetics
2018English

Salvage Surgery for Advanced Non-Small Cell Lung Cancer After Targeted Therapy: A Case Series

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2020English

Systemic Therapy for Previously Untreated Advanced BRAF-mutated Melanoma: Navigating a Shifting Landscape

Immunotherapy
OncologyAllergyImmunology
2017English

Correction: ER Translocation of the MAPK Pathway Drives Therapy Resistance in BRAF-Mutant Melanoma

Cancer Discovery
Oncology
2019English

Encorafenib/Binimetinib for the Treatment of BRAF-mutant Advanced, Unresectable, or Metastatic Melanoma: Design, Development, and Potential Place in Therapy

OncoTargets and Therapy
OncologyPharmacology
2018English

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer

Cancer Research
Cancer ResearchOncology
2016English

Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2015English

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy